XML 18 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Business and Product Line Acquisitions - Additional Information (Detail) (USD $)
 3 Months Ended 6 Months Ended 1 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended
Nov. 30, 2012
Nov. 30, 2011
Nov. 30, 2012
Nov. 30, 2011
Jun. 21, 2011
VeroMara
May 01, 2012
Merial Limited.
Jun. 30, 2011
GeneSeek, Inc.
Apr. 01, 2010
GeneSeek, Inc.
May 31, 2012
GeneSeek, Inc.
May 31, 2011
GeneSeek, Inc.
Nov. 30, 2012
GeneSeek, Inc.
Apr. 01, 2010
GeneSeek, Inc.
Minimum
Apr. 01, 2010
GeneSeek, Inc.
Maximum
Jun. 30, 2011
GeneSeek, Inc.
First Year Contingent Payment
Jun. 30, 2011
GeneSeek, Inc.
Payment for Inventory Purchased and Other Liabilities
Oct. 01, 2012
Macleod Pharmaceuticals
Business Acquisition [Line Items]                                
Cash consideration for purchase of business         $ 813,000 $ 3,200,000   $ 14,050,000               $ 9,918,000
Contingent consideration potential payment         200,000     7,000,000                
Allocation of purchase price for accounts receivable               1,923,000               353,000
Allocation of purchase price for inventory               1,512,000               1,238,000
Allocation of purchase price for fixed assets           340,000   847,000               300,000
Allocation of purchase price for current liabilities               905,000               82,000
Allocation of purchase price for deferred tax liabilities               2,530,000               748,000
Allocation of purchase price for contingent consideration potential payment           600,000   3,583,000   4,370,000 1,447,000         100,000
Other intangible assets estimated lives (years)                       5 years 20 years      
Contingent consideration payment term               3 years                
Change in purchase consideration 40,000 14,000 53,000 40,000           787,000            
Contingent consideration payment             1,856,000   1,263,000         1,537,000 319,000  
Allocation of purchase price for contingent consideration potential payment, adjustment                 154,000              
Estimated revenues from acquisitions         800,000                      
Purchase price allocation for current assets           335,000                    
Purchase price allocation for intangible assets           3,125,000                    
Purchase price allocation for goodwill and intangible assets                               $ 8,957,000